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Introduction
Hemophilia A is a rare X-linked coagulation disorder caused by a broad spectrum of mutations in the F8 gene that lead to a deficiency of clotting factor VIII (FVIII). Patients are classified on the basis of residual plasma FVIII concentration (FVIII:C) as severe (FVIII:C < 1 IU dL À1 ), moderate (1-5 IU dL À1 ), or mild 5-
IU dL

À1
) [1] . The bleeding phenotype in hemophilia A patients correlates inversely with FVIII:C. Severely affected patients present with spontaneous bleeding in joints and muscles. Patients with moderate hemophilia A may bleed spontaneously, and have pronounced bleeding after trauma, whereas, in patients with mild hemophilia A, bleeding is usually restricted to traumatic events.
In this study, we focused on mild/moderate hemophilia A (MHA) patients. The bleeding tendency among MHA patients varies, and is inversely associated with residual FVIII:C. An 18% reduction in joint bleeding frequency has been observed with every IU dL -1 increase in residual FVIII:C in MHA patients who are treated on demand [2] . Moderate hemophilia A patients have the highest risk of joint bleeds, whereas, in mild hemophilia A patients with baseline FVIII:C > 15 IU dL
, joint bleeds rarely occur [2] .
The underlying gene mutation is the most important determinant of residual FVIII:C in hemophilia A patients [3] . MHA is usually caused by missense mutations. Currently,~700 different missense mutations have been reported (P.M. Rallapalli, G. Kemball-Cook, E.G. Tuddenham, K.P.S. Gomez, Manuscript under preparation) [3] [4] [5] [6] . However, within a group of patients with the same F8 missense mutation, FVIII:C may still be variable, as the F8 genotype is not the only determinant of baseline FVIII:C. FVIII is protected against degradation in the circulation by its carrier molecule von Willebrand factor (VWF) [7, 8] . Consequently, VWF plasma levels are associated with FVIII:C. Furthermore, blood group and age indirectly influence FVIII:C by their effect on VWF levels. Individuals with blood group O have significantly lower VWF levels than individuals with blood group non-O, and VWF levels increase throughout life with advancing age [9] [10] [11] .
Our understanding of the pathophysiologic process of the causative genetic event leading to reduced baseline FVIII:C in MHA patients is still limited [12] . This lack of knowledge contributes to ongoing diagnostic uncertainties. Estimates of the variability of FVIII:C in patients with the same F8 genotype and identification of the determinants that influence FVIIII:C in MHA patients are essential for optimizing both diagnostic and individual treatment strategies, and to understand the molecular basis of the development of hemophilia A.
In this article, we present the observed variation in baseline FVIII:C among MHA patients with the same F8 mutation. Furthermore, we assessed the determinants of lowest measured baseline FVIII:C (hereafter referred to as baseline FVIII:C unless otherwise stated). Finally, we analyzed the determinants of inter-and intra-individual variation of all baseline FVIII:C measurements that were available in patients with the three most prevalent F8 missense mutations.
Patients and methods
Study population
Patients were selected from the INSIGHT and RISE studies. The INSIGHT study is an international study on the etiology of inhibitors in patients with a moderate or mild form of hemophilia A (baseline FVIII:C of 2-40 IU dL À1 ) [13] [14] [15] [16] . This large international retrospective cohort study contains clinical data on 2711 patients. The RISE study investigates the response to desmopressin (DDAVP) in MHA patients. Data have been collected from 1376 patients, and 598 of them have also been included in the INSIGHT cohort.
In these studies all MHA patients who were treated with DDAVP and/or FVIII concentrates were included from 19 hemophilia treatment centers (HTCs) between 1980 and 2012. These centers (see Appendix) participated in both studies, and were located in Europe and Australia. The institutional review boards of all participating centers approved the study. As this project involves retrospective data collection, all review boards indicated that informed consent was not required. This study was conducted in accordance with the Declaration of Helsinki.
Patient selection
To reduce the risk of selection bias, we only included patients from centers in which the majority (70%) of the patients were genotyped for routine care. The threshold of 70% was arbitrarily chosen. We only included patients with mutations that were present in at least 10 patients in our cohort. For the present analysis, we excluded patients aged < 10 years to reduce selection bias, as DDAVP/ FVIII administration at a younger age may be associated with a more severe phenotype (Fig. 1) .
First, we analyzed baseline FVIII:C of 346 patients derived from eight HTCs, located in Europe and Australia (Fig. 1) .
Second, we analyzed data of 208 patients with the three most prevalent F8 missense mutations (Arg2169His, n = 55; Arg612Cys, n = 85; and Asn637Ser, n = 68), and analyzed all available 454 one-stage FVIII:C measurements with mixed-model analyses (Fig. 1) .
Data collection
We collected the following data from medical records with a standardized electronic case report form: date of birth, baseline FVIII:C, VWF antigen (VWF:Ag), VWF activity (VWF:Act), F8 mutation, and blood group. Each F8 mutation is reported according to the Human Genome Variation Society-type numbering.
The number of FVIII:C measurements available for a patient varied from one to five. Patients included in the INSIGHT study (those who were ever treated with FVIII concentrate) had a maximum of two baseline FVIII:C measurements recorded. Patients included in the RISE study (those who were ever treated with DDAVP) had a maximum of three baseline FVIII:C measurements recorded. Thus, patients included in both studies had a maximum of five baseline FVIII:C measurements recorded.
FVIII:C measurements
The baseline FVIII:C values used for this analysis were the plasma FVIII coagulant activities measured locally with the one-stage clotting assay. We collected all baseline FVIII:C measurements that were available without treatment with DDAVP or FVIII concentrate in the 72 preceding hours. Statistical analyses Figure 1 shows an overview of the statistical analyses. Levene's test for equality of variances was used to compare the observed variation in baseline FVIII:C among different mutation groups.
Inter-individual variance in baseline FVIII:C was addressed by univariate analyses to explore associations of F8 mutation, VWF and age with baseline FVIII:C. We conducted a sensitivity analysis for patients in whom VWF levels were known at the exact date of the baseline FVIII:C measurement. An unpaired t-test was used to compare baseline FVIII:C in patients with blood group O and those with blood group non-O.
First, multiple linear regression analysis was performed to evaluate the variation in baseline FVIII:C for different mutation groups, with adjustment for HTC and age. The adjusted R 2 represents the percentage of variance in baseline FVIII:C explained by this model.
In a second approach, we addressed both inter-and intra-individual variation by including all baseline FVIII: C measurements that were available for patients with one of the three most prevalent F8 missense mutations. We used linear mixed models to analyze determinants of all available baseline FVIII:C measurements. The linear mixed model allows for the investigation of group differences while controlling for the non-independency of data (that is, more than one baseline FVIII:C measurement was performed in one patient, resulting in related measurements within individuals). All available baseline FVIII:C measurements, F8 gene mutation, HTC and the age at time of baseline FVIII:C measurement were included in the model. We included random intercepts for the HTCs and patients. Random intercepts per HTC were included because there may be subtle differences in the patient populations that they serve. We included random intercepts per patient to allow for the fact that each individual has a unique FVIII:C. Hence, repeated observations in individuals will generally demonstrate less variation than in observations in independent individuals. Age and F8 mutation were included as fixed effects in the mixed-effect models, as these variables were the focus of our analysis. We used the method proposed in equation 26 by Nakagawa et al. to calculate the adjusted R 2 for mixed-effects models [17] .
Third, the same linear mixed-model analysis was performed in each of the three largest mutation groups, in order to quantify the explained variation in age at time of baseline FVIII:C measurement specifically per mutation group. Estimated marginal means are presented to compare the main effects of the different missense mutations contributing to baseline FVIII:C.
Statistical analyses were performed with SPSS for Windows, version 22.0 (SPSS, Chicago, IL, USA). A P-value of < 0.05 was considered to be statistically significant.
Results
Patient characteristics
We selected 346 patients aged ≥ 10 years who carried missense mutations that were present in at least 10 patients (Fig. 1) . The patient characteristics are shown in Table 1 . The 346 patients had 13 different missense mutations, and a total of 759 one-stage FVIII:C measurements had been performed. The variation in baseline FVIII:C observed in patients with the same F8 missense mutation is shown in Fig. 2 . We observed a significant difference in the variations of baseline FVIII:C between the different mutation groups (Levene's test, P < 0.001).
Univariate analyses of determinants for baseline FVIII:C in 346 patients
We analyzed the effects of F8 mutation, VWF plasma level, blood group, age, and HTC. Compared to FVIII:C in patients with Arg612Cys, FVIII:C was significantly different in patients with 10 other F8 missense mutations (P = 0.031 for Arg550Cys, and P < 0.001 for the other nine mutations). For two of the mutations (Arg1960Gln and Tyr530Cys), no association with baseline FVIII:C could be demonstrated (P = 0.404 and P = 0.063, respectively). The analysis of the association between baseline FVIII:C and VWF:Ag or VWF:Act measured on the same day was impaired by low patient numbers (available in 42 and 35 patients, respectively), and associations could therefore not be detected. As the F8 mutation may be a more important determinant of baseline FVIII:C than VWF level, we also analyzed the association between baseline FVIII:C and VWF level separately within the largest group of patients with the same mutation (Arg612Cys; n = 85). In this mutation group, we did find a significant association between baseline FVIII:C and VWF:Act (P = 0.003).
For all mutations grouped together, we did not observe a difference in baseline FVIII:C between patients with blood group O and those with blood group non-O (available in 155 patients). Older age was associated with a higher baseline FVIII:C of 0.064 IU dL À1 for each year (Fig. 3) .
Determinants of baseline FVIII:C in 346 patients
A multiple linear regression model was constructed to explain the observed variation in baseline FVIII:C according to different F8 mutation groups, adjusted for age and HTC. The adjusted R 2 represents the percentage of variation in baseline FVIII:C explained by this model. A significant regression equation was found (P < 0.001). Age and genotype, adjusted for HTC, explained 59% of the observed inter-individual variation in baseline FVIII:C. Compared to FVIII:C in patients with Arg612Cys, FVIII: C was significantly different in patients with eight other F8 missense mutations (Table S1 ). When Arg612Cys was used as the reference group, patients with Pro149Arg, Val502Gly, Arg550Cys, Arg2169His and Gln2265Arg mutations had significantly lower baseline FVIII:C and patients with Arg550His, Asn637Ser and Arg717Trp had significantly higher baseline FVIII:C (Fig. 2) . Four mutations were not significant in this model. Patients with Arg1960Gln showed a lower baseline FVIII:C, whereas those with Arg2178Cys, Leu644Val and Tyr530His showed a higher baseline FVIII:C, than the reference group, but these observed differences in baseline FVIII:C from the Arg612Cys group were not significant ( Fig. 2 ; Table S1 ). The results of a post hoc power analysis are shown in Table S2 . Figure 4 shows the mutations and the associations with baseline FVIII:C grouped per domain of the FVIII protein.
Baseline FVIII:C increased 0.066 IU dL À1 for every year increase in age. From this analysis it appeared that in one of the HTCs, which contributed only one patient for the analyses, baseline FVIII:C was 6 IU dL À1 lower than in the other HTCs.
Construction of a model to explain variation in baseline FVIII:C within the three largest mutation groups
To address intra-and interpatient variation, we analyzed patients from the three largest 80 100 Fig. 3 . We observed an association between baseline plasma concentration of factor VIII (FVIII:C) and age (n = 345, P = 0.008, adjusted R 2 = 2%).
[n = 55]), using data of all FVIII:C measurements adjusted for age and HTC. There were 454 baseline FVIII:C measurements from 208 patients available.
Patients with Arg612Cys and Arg2169His had lower baseline FVIII:C than those with Asn637Ser (point estimates of À 7.04 and À 16.70, respectively, with P < 0.001; Table 2 ).
The variation in FVIII:C measurements within an individual at different time points explained 45% of the total observed variation in FVIII:C measurements adjusted for F8 mutation, age and HTC (Table S3) . FVIII:C was 0.09 IU dL À1 higher for every year that patients aged (P < 0.001). Subsequently, the linear mixed model for each separate mutation group showed different effects of age among the three mutation groups. The effect of age was stronger in patients with Arg612Cys than in patients with Arg2169His or Asn637Ser (point estimate of annual increase in baseline FVIII:C of 0.13, 0.07, and 0.04, respectively). Age at time of baseline FVIII:C measurement explained 13%, 5% and 0.6% of the observed variation in patients with Arg612Cys, Arg2169His, and Asn637Ser, respectively (Table S4) .
Discussion
In this retrospective cohort of 346 patients, we found, among groups of at least 10 patients with the same F8 missense mutation, large inter-and intra-individual variation in baseline FVIII:C. Age and genotype, adjusted for HTC, explained 59% of the observed inter-individual variation in baseline FVIII:C. However, compared to FVIII:C in patients with Arg612Cys, baseline FVIII:C was not significantly different in patients with four other F8 missense mutations.
We could only find an association between baseline FVIII:C and VWF in a separate subanalysis, probably owing to a lack of power, as data on VWF levels were only available for a small group of patients, because we did not have information on the exact date of VWF level measurement in patients from the INSIGHT study. Another reason for not finding an association between baseline FVIII:C and VWF might be that MHA patients have little variation in VWF levels. When we analyzed the variation of all available baseline FVIII:C measurements in a subgroup of 208 patients with the three most prevalent missense mutations, it appeared that the intraindividual variation explained 45% of the total observed variation in all baseline FVIII:C measurements.
It is known that both FVIII and VWF levels increase with age. VWF is produced by endothelial cells. The increase in FVIII:C is believed to be secondary to the increase in VWF level. Vischer hypothesized that increased arterial rigidity in older patients might determine the increased secretion of VWF [18] . However, the exact signal transduction events involved in endothelial function with increasing age are poorly understood [10, 11] . One of the factors contributing to the observed intraindividual variation is age. The effect of age on baseline FVIII:C was different for each of the three mutations. The strongest increase in FVIII:C for advancing age was observed in patients with the Arg612Cys missense mutation, with an explained variation of 13% (n = 85), whereas age explained only 0.6% in patients with Asn637Ser (n = 68).
Both mutations are located in the A2 domain and cause impaired intracellular trafficking of FVIII, resulting in an FVIII secretion defect [19] . It is possible that the impairment becomes less severe as patients age, so that FVIII can be secreted better and FVIII:C increases.
Although Arg612Cys and Asn637Ser are believed to cause the same type of defect, age influences baseline FVIII:C differentially between the two mutations (13% versus 0.6%, Table S4 ). Apparently, intracellular trafficking of FVIII is more severely impaired by Asn637Ser. We do not have an explanation for the differences between these two mutations in the same domain, but it is possible that the introduction of a cysteine residue has a different functional effect than an asparagine to serine substitution.
The effect of age will be more evident when initial levels are higher, owing to a proportional incremental increase. This does not explain the discrepancy between the mean FVIII:C values in the Asn637Ser group and the Arg612Cys group (mean FVIII:C of 18.3 IU dL À1 and 25.7 IU dL À1 respectively, with comparable confidence intervals; Table 2 ).
As FVIII:C tends to increase with age in healthy individuals, it might be more interesting to study the mutations that do not result in FVIII levels increasing with age. Apparently, Asn637Ser and Arg2169His cause such strong impairment that age cannot overcome this effect on FVIII:C. Arg2169His is located in the C1 domain, and this defect is known to impair VWF binding [20] . Therefore, VWF cannot contribute to the increase in FVIII:C with age. As age also does not contribute to a large extent in patients with this mutation, FVIII:C values are likely to be determined by additional determinants.
Limitations and strengths
This large, international cohort of MHA patients provides data on the association between F8 missense mutations and baseline FVIII:C. Our study is unique in its large size. Owing to the broad spectrum of missense mutations associated with MHA, knowledge of the association between F8 mutation and baseline FVIII:C is difficult to obtain, as smaller studies lack the statistical power to analyze this. The high number of patients in our study could only be included because of the participation of multiple HTCs.
As we used the locally measured baseline FVIII:C, assay discrepancies between HTCs may increase the observed variation in baseline FVIII:C. Fortunately, all HTCs used the same type of assay, i.e. the one-stage clotting assay.
However, there is increased awareness that the assay method used to measure FVIII:C may explain some of the variability of FVIII:C in MHA patients [21] [22] [23] . In 40% of the patients, the level determined with the onestage clotting assay has been found to be up to twice as high as that determined with the two-stage clotting or chromogenic clotting assays. It has been proposed that chromogenic assays may better predict bleeding phenotype [12, 21] . If only a one-stage assay is performed in the diagnostic work-up, then FVIII:C may be overestimated and the bleeding risk may be underestimated in these patients [12] .
To account for assay discrepancies between HTCs, we adjusted for HTC in the multiple linear regression model and in the linear mixed-model analysis. Moreover, the great variety in missense mutations hampered more specific analyses of the effects of the different mutations. We reduced selection bias by restricting our analysis to all patients from centers that had genotyped at least 70% of their patients, and by excluding patients aged < 10 years.
Clinical significance
Baseline FVIII:C is multifactorial in origin, and not only determined by the F8 mutation. This is important to understand for correct diagnosis and in order to achieve a more personal approach in MHA care.
In our cohort, age and genotype, adjusted for HTC, explained 59% of the observed inter-individual variation in baseline FVIII:C. Compared to FVIII:C in patients with Arg612Cys, FVIII:C was significantly different in patients with eight other F8 missense mutations. This awareness is essential in diagnostic patient management, as patients with the same mutation might have a different baseline FVIII:C.
Older age was associated with higher baseline FVIII:C, and the effect of age was different in patients from the three most prevalent mutation groups.
As baseline FVIII:C increases with age, it is questionable whether the phenotype becomes milder with advanced age. Baseline FVIII:C also increases in healthy individuals; this increase in older individuals might be required to maintain hemostasis in the more fragile circumstances of old age [24] . Coagulation factor levels above the 'normal' range may reflect a physiologic response to the increased hemostatic requirement of old age, in analogy to higher physiologic FVIII:C at the end of pregnancy [25] .
Future studies
To investigate the relationship between mutation, baseline FVIII:C, and bleeding phenotype, data on the severity and frequency of bleeding in MHA need to be collected.
With this information, it is possible to investigate whether baseline FVIII:C is a valid indicator of bleeding phenotype. It is important to stress that both one-stage and chromogenic FVIII:C assays should be used, as there is ongoing discussion on which assay most appropriately reflects the clinical phenotype in patients with discrepancies between the two assays [21] . The processes from mutation to protein formation might be more complex than we think. Moreover, alterations of genes other than F8, e.g. those involved in the fibrinolytic pathway, may also influence the bleeding phenotype, and should be further investigated as potential indicators of bleeding risk for MHA patients [12] . Future studies to explain the remaining 41% of the observed variation in baseline FVIII:C should include data on VWF levels.
Conclusion
In this large cohort of patients with MHA, age and genotype, adjusted for HTC, explained 59% of the observed inter-individual variation in baseline FVIII:C. Compared to FVIII:C in patients with Arg612Cys, FVIII:C was significantly different in patients with eight other F8 missense mutations. Furthermore, intra-individual variation accounted for 45% of the variation observed within the three largest mutation groups. The increase in baseline FVIII:C with age varies between different mutation groups. Our results indicate that FVIII:C is not exclusively determined by F8 genotype. Identification of additional determinants of FVIII:C may help to further improve treatment strategies in MHA patients. Moreover, insights into other factors may provide potential novel targets for the treatment of MHA. Table S1 . Multiple linear regression analyses of baseline FVIII:C predicted by F8 mutation, age and HTC. Table S2 . Power analyses mutation groups. Table S3 . Mixed-model analyses in three largest mutation groups. Table S4 . Mixed-model analyses per largest mutation group.
